Company Analysis
Sign in

BioAtla, Inc. (BCAB)

OTC: BCAB · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.9
◀ Past 4.8● Present 4.0▶ Future 5.7
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

46 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioAtla, Inc.’s names, not what it holds today.

Patents granted
46
46 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 5 in 2024 and 7 in 2023
Applications published
82
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'10'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
Biotechnology8
Analysis of biological materials3
Organic fine chemistry2
Computer technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BioAtla, Inc. its own name
US, as the owner printed on each patent
46 granted
76 published
BioAtla, LLC its own name
named as the applicant on its applications, in US
0 granted
6 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 18, 202512,473,360Multi-specific antibody constructsPharmaceuticalsBioAtla, Inc.
Sep 30, 202512,427,347Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereofPharmaceuticalsBioAtla, Inc.
Jan 7, 202512,187,801Chimeric antigen receptors against AXL or ROR2 and methods of use thereofBiotechnologyBioAtla, Inc.
Oct 8, 202412,110,611Conditionally active biological proteinsBiotechnologyBioAtla, Inc.
May 7, 202411,976,381Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hostsOrganic fine chemistryBioAtla, Inc.
Feb 13, 202411,897,959Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereofPharmaceuticalsBioAtla, Inc.
Jan 23, 202411,879,011Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereofPharmaceuticalsBioAtla, Inc.
Jan 2, 202411,859,007Humanized anti-CD73 antibodiesAnalysis of biological materialsBioAtla, Inc.
Dec 26, 202311,851,499Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereofPharmaceuticalsBioAtla, Inc.
Dec 5, 202311,834,472Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereofPharmaceuticalsBioAtla, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0276075METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATESPharmaceuticalsBioAtla, Inc.
May 29, 20252025/0170264ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOFPharmaceuticalsBioAtla, Inc.
May 22, 20252025/0161472CANCER TREATMENT WITH A CONDITIONALLY ACTIVE ANTI-ROR2 ANTIBODY-DRUG CONJUGATEPharmaceuticalsBioAtla, Inc.
Jan 23, 20252025/0026840CHIMERIC ANTIGEN RECEPTORS AGAINST AXL OR ROR2 AND METHODS OF USE THEREOFBiotechnologyBioAtla, Inc.
Dec 19, 20242024/0417886CONDITIONALLY ACTIVE BIOLOGICAL PROTEINSBiotechnologyBioAtla, Inc.
Dec 5, 20242024/0400659CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASESPharmaceuticalsBioAtla, Inc.
Aug 8, 20242024/0263354SIMULTANEOUS, INTEGRATED SELECTION AND EVOLUTION OF ANTIBODY/PROTEIN PERFORMANCE AND EXPRESSION IN PRODUCTION HOSTSOrganic fine chemistryBioAtla, Inc.
Jun 20, 20242024/0199746ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOFPharmaceuticalsBioAtla, Inc.
May 2, 20242024/0141035Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses ThereofPharmaceuticalsBioAtla, Inc.
Apr 11, 20242024/0117067CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOFPharmaceuticalsBioAtla, Inc. · patent 12,427,347 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Biotechnology 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BCAB · research, not advice